TCT 2018 | RADIOSOUND-HTN: Testing Different Renal Ablation Techniques and Devices

The clinical efficacy of renal endothelial sympathetic denervation using both radiofrequency and ultrasound endoscopy in the treatment of hypertension has already been proven. This is the first work comparing different techniques and technologies used to this end, which warranted its publication in Circulation.

Intentando reducir la insuficiencia renal post TAVIPatients with resistant hypertension were randomized 1:1:1 to: 1) radiofrequency denervation of the main renal arteries; 2) radiofrequency denervation of the main renal arteries, side branches, and accessories, or 3) ultrasound denervation of the main renal arteries. The primary endpoint was modification of systolic daytime ambulatory blood pressure at 3 months.

 

The study included 120 patients with mean daytime blood pressure 153/86 ± 12/13 mmHg.

 

At 3 months, systolic daytime blood pressure fell by 9.5 ± 12.3 mmHg in the whole cohort.


Read also: TCT 2018 | NEOPRO: A Registry for Acurate neo and Evolut PRO.


The drop in blood pressure was more significant in the ultrasound-guided group.

 

In patients with resistant hypertension, renal denervation using endovascular ultrasound proved to be superior to radiofrequency ablation, while the combined denervation of side branches and accessories resulted in no significant difference as regards outcomes compared with radiofrequency of the main renal arteries only.

 

Original title: A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients with Resistant Hypertension: (RADIOSOUND-HTN).

Presenter: Philipp Lurz.

 

RADIOSOUND-HTN-presentación

RADIOSOUND-HTN-articulo-original


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....